期刊文献+

他汀类药物对C反应蛋白及脑梗死的作用 被引量:4

Statins Effects on C-reactive Protein and Cerebral Infarction
暂未订购
导出
摘要 C反应蛋白(CRP)是一种由肝脏产生的急性时相蛋白,可用免疫学方法进行测定。脑梗死的重要病理基础是动脉粥样硬化,而CRP和脂质代谢紊乱则是动脉粥样硬化发生、发展的重要启动子。通过对CRP及动脉粥样硬化致病机制、他汀类药物作用的研究,认为他汀类药物在脑梗死的防治方面具有不可替代的作用。该文就CRP的生物学特征、他汀类药物对CRP及动脉粥样硬化性脑梗死的相互关系进行综述。 As an acute phase protein, C-reactive protein(CRP) is mainly produced by the liver, and can be measured by immunological method. Atherosclerosis,as the most important pathological basis of cerebral infarction, in development of which CRP and 'lipid metabolism disorder play the role of key promoters. Based on the research of CRP and pathogenic mechanism of atherosclerosis, statin drug action, it's considered that statins have an irreplaceable role in the prevention and treatment of atherosclerosis and cerebral infarction. Here is to make a review of the biologicaI characteristics of CRP, the interrelation between statins, CRP and atherosclerotic cerebral infarction.
出处 《医学综述》 2013年第11期1924-1927,共4页 Medical Recapitulate
基金 湖南省卫生厅项目(2B2009118)
关键词 他汀类药物 C反应蛋白 脑梗死 动脉粥样硬化 Statins C- reactive protein Cerebral infarction Atherosclerosis
  • 相关文献

参考文献1

二级参考文献4

共引文献8

同被引文献42

  • 1叶平.2012他汀类药物安全性再认识[J].中国医学前沿杂志(电子版),2012,4(8):1-4. 被引量:13
  • 2李建军.如何认识调脂药物的调脂外作用[J].中国医学前沿杂志(电子版),2012,4(8):11-13. 被引量:6
  • 3韩薇,李为民.他汀类药物独立于降脂作用以外的多效性评价[J].中华老年医学杂志,2005,24(11):875-877. 被引量:2
  • 4杨诗杰,苏汝好,项岚,乔海灵.降血脂药的应用现状及研究进展[J].医药论坛杂志,2006,27(1):90-92. 被引量:31
  • 5Fukumoto Y,Libby P,Rabkin E,et al.Statins alter smooth muscle cell accumulation and collagen content in established atheroma of wan- tanabe heritable hyperlipidenaic rabbits[J].Circulation ,2001,103 (7): 993 -999.
  • 6Carl JV,Antonio MG,Craig TB.The evolving role of statins in the management of atherosclerosis[J].J Am Coil Cardio1,2000,35 ( 1 ) : 1-10.
  • 7Kearney D,Fitzgerald D.The anti-thrombotic effects of statins[J].J Am Coll Cardiol, 1999,33(5) : 1305-1307.
  • 8Cohen DE,Anania FA ,Chalasani N.For the National Lipid Association Statin Safety Task Force Liver Expert Panel.An assessment of statin safety by hepatologists[J].Am J Cardiol, 2006,97 (8A) : 77C-81C.
  • 9Armitage J.The safety of statins in clinical practice [J].Lancet, 2007,370(9601 ) : 1781-1790.
  • 10Erickson KF,Japa S,Owens DK,et al.Cost-effeetiveness of statins for primary cardiovascular prevention in chronic kidney disease[J].J Am Coil Cardio1,2013,61 (12) : 1250-1258.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部